ANCA-Associated Vasculitis Research Reagents

ANCA-associated vasculitis (AAV) encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) — a group of systemic small-vessel vasculitides characterized by necrotizing inflammation and autoantibodies against neutrophil cytoplasmic antigens. Anti-proteinase 3 (PR3-ANCA/c-ANCA) is predominantly associated with GPA and higher relapse risk, while anti-myeloperoxidase (MPO-ANCA/p-ANCA) is characteristic of MPA. ANCA binding to primed neutrophils triggers degranulation, NET formation, complement activation via the alternative pathway (C5a amplification loop), and endothelial damage. Treatment advances include rituximab (anti-CD20, now first-line for remission induction), avacopan (C5a receptor inhibitor, first complement-targeting therapy for AAV as glucocorticoid-sparing), and mepolizumab (anti-IL-5) for EGPA.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

ANCA-Associated Vasculitis Research Reagents — key pathogenic pathways including MPO/PR3 autoantibodies, neutrophil activation, complement C5a/C5aR1 amplification loop, and IL-5/eosinophil-driven EGPA

Fig. 1 Key pathogenic pathways in ANCA-associated vasculitis. Anti-MPO/anti-PR3 autoantibodies activate neutrophils; C5a/C5aR1 amplification loop drives neutrophil recruitment; IL-5 mediates eosinophil activation in EGPA. Key research targets highlighted in orange.

abinScience provides validated anti-MPO matched-pair monoclonal antibodies (5 clones) for ANCA diagnostic ELISA development, PRTN3/PR3 recombinant proteins, the broadest anti-C5aR1 reference antibody panel (5 reference antibodies for avacopan mechanism research), and anti-IL-5 reference antibodies (mepolizumab, reslizumab, depemokimab) for EGPA research. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

MPO (Myeloperoxidase) — Anti-MPO (p-ANCA) autoantibodies define MPA and are associated with renal-limited vasculitis. MPO is a lysosomal enzyme in neutrophil azurophilic granules that generates reactive oxygen species during respiratory burst. abinScience offers 5 anti-human MPO matched-pair monoclonal antibodies (clones 1A355, 1A356, 1A524, 1A525, 1A526), anti-MPO polyclonal antibody, anti-mouse MPO recombinant antibody (clone 6D6), and human/mouse MPO recombinant proteins for ANCA diagnostic sandwich ELISA development, neutrophil activation assays, and MPO enzymatic activity studies.
→ Browse MPO antibodies & proteins

PR3 / PRTN3 (Proteinase 3) — Anti-PR3 (c-ANCA) autoantibodies are predominantly associated with GPA and carry a higher relapse risk compared to anti-MPO. PR3 is a serine protease in neutrophil azurophilic granules with roles in inflammation and apoptosis. abinScience offers human PRTN3 recombinant proteins (N-GST and N-His tagged) and mouse PRTN3 recombinant protein for anti-PR3 diagnostic ELISA development, PR3 epitope mapping, and neutrophil degranulation studies.
→ Browse PR3 / PRTN3 proteins

C5a / C5aR1 (CD88) — The C5a/C5aR1 amplification loop is the central complement pathway driving neutrophil activation and vascular damage in AAV. C5a primes neutrophils for ANCA-mediated activation, creating a self-amplifying inflammatory cascade. Avacopan (C5aR1 antagonist) is the first complement-targeting, glucocorticoid-sparing therapy approved for AAV. abinScience offers 5 anti-C5aR1 reference antibodies (Avdoralimab, ADC-1004, MOR210, Izastobart, G2_anti-C5aR), anti-C5a reference antibody (MEDI7814), and anti-C5aR1 recombinant antibody (SAA0039) for avacopan mechanism studies, complement pathway dissection, and neutrophil priming research.
→ Browse C5a / C5aR1 antibodies

IL-5 (EGPA) — IL-5 drives eosinophil differentiation, activation, and survival, and is the key pathogenic cytokine in eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab (anti-IL-5) is approved for EGPA as a steroid-sparing therapy. abinScience offers anti-IL-5 reference antibodies covering the full pipeline: mepolizumab, reslizumab, depemokimab, and varokibart, plus anti-IL-5Rα/CD125 reference antibody (benralizumab), supporting mechanism-of-action studies, biosimilar characterization, and eosinophil biology research across AAV subtypes.
→ Browse IL-5 antibodies & proteins

References

1. Kitching AR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. DOI

2. Jayne DRW, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599-609. DOI

3. Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. DOI